ClinicalTrials.gg

Program

mevrometostat

Also written as “PF-06821497”, “Mevrometostat (PF-06821497)” and “Mevrometostat”.

In Pfizer's pipeline, EZH2 inhibitor. Its studies are mostly in Prostatic Neoplasms · Small Cell Lung Carcinoma, led by Pfizer.

Furthest: phase 3, since Jul 25, 20247 company-led studies, 4 open or runningNext primary completion: Feb 28, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer74 open or runningphase 3since Jul 25, 2024Feb 12, 2018Feb 28, 2027phase 3 · NCT06551324
  • Named in Pfizer’s own pipeline as mevrometostat PF-06821497, phase 3, as of Nov 3, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 12, 2018First study: phase 1 study in Small Cell Lung CarcinomaFirst studyNCT03460977 · 453 planned · United States, Bulgaria, China and more
  2. Mar 2, 2023Phase 1 study in HealthyNCT05767905 · 18 enrolled · United States
  3. Apr 12, 2024Phase 1 study in Healthy ParticipantsNCT06392230 · 6 enrolled · Netherlands
  4. Jul 25, 2024Phase 3 study in Prostatic NeoplasmsNCT06551324 · 609 enrolled · United States, Argentina, Australia and more
  5. Sep 10, 2024Phase 3 study in Metastatic Castration-Resistant Prostate CancerNCT06629779 · 900 planned · United States, Argentina, Brazil and more
  6. Oct 24, 2024Phase 1 study in HealthyNCT06661694 · Belgium
  7. Apr 15, 2025Phase 3 study in Prostatic NeoplasmsNCT07028853 · 1,000 planned · United States, Argentina, Australia and more
  8. Oct 30, 2026Primary completion moved from 2026-12-28 to 2027-02-28Date moved laterphase 3 · +2 months · NCT06551324
  9. Oct 30, 2026Primary completion moved from 2026-12-02 to 2027-09-30Date moved laterphase 3 · +10 months · NCT06629779

Ahead

  1. Feb 28, 2027Primary completion: phase 3 study in Prostatic NeoplasmsNCT06551324
  2. Sep 30, 2027Primary completion: phase 3 study in Metastatic Castration-Resistant Prostate CancerNCT06629779
  3. Apr 20, 2028Primary completion: phase 1 study in Small Cell Lung CarcinomaNCT03460977
  4. Sep 12, 2028Primary completion: phase 3 study in Prostatic NeoplasmsNCT07028853

TargetBeta

“EZH2 inhibitor”the company's pipeline, read by Claude · source
“An orally available selective inhibitor of the histone lysine methyltransferase (HMT) enhancer of zeste homolog 2 (EZH2), with potential antineoplastic activity. Upon oral administration, mevrometostat selectively targets, binds to and inhibits the activity of EZH2. Inhibition of EZH2 specificall…”NCIt, read by Claude
“An orally available selective inhibitor of the histone lysine methyltransferase (HMT) enhancer of zeste homolog 2 (EZH2), ”NCIt, by rule

Other programs on EZH2

ProgramCompanyFurthest phaseStudies
zeprumetostatruleJiangsu HengRui Medicinephase 317
TR115ruletarapeutics-science-incphase 33
tulmimetostatNovartisphase 23
EZH1/2 Inhibitor HH2853ruleHaihe Biopharmaphase 22
valemetostatruleDaiichi Sankyophase 11

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07028853Prostatic Neoplasms · United States, Argentina, Australia and more3RecruitingSep 12, 20281,000
NCT06661694Healthy · Belgium1WithdrawnSep 8, 20250
NCT06629779Metastatic Castration-Resistant Prostate Cancer · United States, Argentina, Brazil and more3RecruitingSep 30, 2027900
NCT06551324Prostatic Neoplasms · United States, Argentina, Australia and more3Active, not recruitingFeb 28, 2027609
NCT06392230Healthy Participants · Netherlands1CompletedNov 11, 20246
NCT05767905Healthy · United States1CompletedJun 20, 202318
NCT03460977Small Cell Lung Carcinoma · United States, Bulgaria, China and more1RecruitingApr 20, 2028453

How it is read

Names in the registry

  • “PF-06821497”, 2 entries
  • “Mevrometostat (PF-06821497)”, 1 entry
  • “Mevrometostat”, 1 entry
  • “PF-06821497 Treatment A”, 1 entry
  • “PF-06821497 Treatment B”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.